Latest Drug development biotechnology articles and news on biotech industry leaders, emerging biotech companies in Spain

Ona Therapeutics Raises $86.6 Million Series B to Advance First-in-Class ADCs into Clinical Development

by Ysios Capital

27 days ago
ONA-255, ONA-389, ADCs, Mérieux Equity Partners, Columbus Venture Partners, Ona Therapeutics

Proceeds to support clinical development of lead first-in-class program ONA-255 in breast cancer, toward clinical proof of concept, and advance ONA-389 in colorectal cancer

CONNECTA Therapeutics inicia un ensayo clínico de Fase IIa con CTH120, un modulador de la neuroplasticidad first-in-class para el síndrome X frágil

by Connecta Therapeutics

21 days ago
síndrome X frágil (SXF), receptor de tropomiosina quinasa B (TrkB), neuroplasticidad

CTH120 es un tratamiento potencialmente modificador del síndrome X frágil, una enfermedad rara sin tratamiento específico aprobado a día de hoy que afecta gravemente a la cognición y la conducta....

ORYZON Presents Updated Positive Clinical Data for Iadademstat in Acute Myeloid Leukemia (AML) at European Hematology Association (EHA) 2026 Annual Congress

by Oryzon Genomics

20 days ago
Iadademstat, Myeloid Leukemia (AML)

In first line AML (ALICE-2 trial), iadademstat with azacitidine and venetoclax showed high levels of clinical activity, with 100% (18/18) ORR, 89% (16/18) CRc and 78% (14/18) CR, and continued to demo...

Vall d’Hebron leads a European project to test a new, more effective and less toxic drug against childhood cancer

by Vall d’Hebron

16 days ago
ibrilatazar (ABTL0812), neuroblastoma

The PHOENIX project, involving 13 European institutions, will evaluate for the first time in paediatric patients the drug ibrilatazar from AbilityPharma in a phase I/II clinical trial.

Shilpa Biocare invests in Gate2Brain, an IRB Barcelona spin-off, to advance an innovative therapeutic candidate for brain cancer

by IRB Barcelona - Instituto de Investigación Biomédica

14 days ago
Gate2Brain, Shilpa Biocare, G2B-002

Gate2Brain signs a strategic partnership with Shilpa Biocare, including a €7 million investment for a 30.4% equity stake in the company.

InnoUp Farma, backed by Sodena, Successfully Completes Phase 1 Trial of INP20, Its Innovative Oral Immunotherapy for Peanut Allergy

by Sodena

6 days ago
Food Allergy Treatment, Sodena, INP20, InnoUp Farma

Unlike other therapies currently available or under development, INP20 is not designed to desensitise patients to the allergen. Instead, it aims to replicate the biological signals generated by the gu...

Telum Therapeutics Secures €18 Million Series A Financing to Advance Lead Antimicrobial Program into Clinical Development

by Telum Therapeutics

8 hours ago
Telum Therapeutics, Inveready, Sodena, Invivo Partners, Clave Capital, CDTI, AMR Action Fund, Acinetobacter baumannii

Telum Therapeutics, a biotechnology company leveraging proprietary metagenomic datasets, synthetic biology and generative AI to develop novel antimicrobial therapies, has announced the successful comp...